Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bayer ag - germania - gadobutrolum - sol. inj. in seringa preumpluta - 1mmol/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

Unió Europea - romanès - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - alte preparate antianemice - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Unió Europea - romanès - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenți antitrombotici - prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 pentru haemodynamically instabil pe pacienți). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 și 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unió Europea - romanès - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemie, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Unió Europea - romanès - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresoare - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) este indicat pentru tratamentul pacienților adulți cu mielom multiplu netratați anterior, care nu sunt eligibili pentru transplant. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unió Europea - romanès - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - toate celelalte produse terapeutice - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sun pharmaceutical industries europe b.v. - olanda - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare